Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Melanoma Clinical Trial

Official title:

A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02143050
• Other study ID #: BCC-MEL-14-01
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: September 2014
• Est. completion date: November 17, 2017

Study information

• Verified date: November 2023
• Source: University of Louisville
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.

Description:

The study will be a single-arm, single center, uncontrolled phase I/II trial to estimate the safety of the combined treatments and then estimate the efficacy in terms of objective response rate in patients with stage IIIC and Stage IV melanoma treated with dabrafenib/trametinib and metformin.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 17, 2017
• Est. primary completion date: November 17, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Male or female patients > 18 years of age
• Patients with histologically confirmed BRAFV600E melanoma (Stage IIIC or
• Stage IV, American Joint Commission on Cancer)
• Eastern Cooperative Oncology Group Performance Status of 0 to 2
• Life expectancy > 3 months
• At least 1 site of radiographically measurable disease by RECIST 1.1
• Adequate hematologic, renal, and liver function as defined by laboratory values

performed within 42 days prior to initiation of dosing:

• Absolute neutrophil count > 1.0 x 10?/L
• Platelet count > 50 x 10?/L
• Hemoglobin > 8 g/dL
• Serum creatinine < 2 x upper limit of normal
• Total serum bilirubin < 3 x ULN
• Serum aspartate transaminase or serum alanine transaminase < 3 x ULN, and < 4 x ULN if liver metastases are present
• Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician
• Pre-menopausal females and females < 2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of the study drug
• Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for > 1 year
• Before study entry, written informed consent must be obtained from the patient prior to performing any study related procedures

Exclusion Criteria:

• Prior treatment with Vemurafenib or Dabrafenib
• Known hypersensitivity to Metformin or any of its components
• Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment or have not recovered from side effects of all radiation related toxicities to Grade < 1, except for alopecia
• Pregnant, breast feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures
• Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Dabrafenib

• Trametinib

• Metformin

Locations

Country	Name	City	State
United States	James Graham Brown Cancer Center	Louisville	Kentucky
United States	James Graham Brown Cancer Center-Universityof Louisville	Louisville	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
University of Louisville	James Graham Brown Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Observation of two CTCAE drug related grade 4 toxicities in six patients.	During phase I, six patients will be enrolled and monitored for toxicities. If drug related deaths occur or more than two drug related CTCAE grade 4 toxicities occur the trial will be suspended. Phase II will estimate the efficacy of the drugs, enrolling 20 patients during stage 1 with an upper limit of 39 for the 2nd stage.	Duration of phase I portion, approxiately 6 months
Primary	Clinical Response Rate	Phase II will study the efficacy of the drugs enrolling 20 patients during stage I with an upper limit of 39 for the 2nd stage.	6 years
Secondary	To estimate the overall survival rates.	Patients will be contacted every 3 months following treatment administration for up to three years to obtain survival data.	Approximately 3 years
Secondary	To explore the effect of other covariates on overall survival	To identify demographic, disease and treatment related effects on overall survival.	3 years